150 related articles for article (PubMed ID: 23763495)
1. Investigation of parameters influencing incorporation, retention and cellular cytotoxicity in liposomal formulations of poorly soluble camptothecin.
Whitaker RD; Ingebrigtsen SG; Naderkhani E; Skar ML; Flaten GE
J Liposome Res; 2013 Dec; 23(4):298-310. PubMed ID: 23763495
[TBL] [Abstract][Full Text] [Related]
2. Liposomal formulations of poorly soluble camptothecin: drug retention and biodistribution.
Flaten GE; Chang TT; Phillips WT; Brandl M; Bao A; Goins B
J Liposome Res; 2013 Mar; 23(1):70-81. PubMed ID: 23210622
[TBL] [Abstract][Full Text] [Related]
3. Biologically active camptothecin derivatives for incorporation into liposome bilayers and lipid emulsions.
Lundberg BB
Anticancer Drug Des; 1998 Jul; 13(5):453-61. PubMed ID: 9702210
[TBL] [Abstract][Full Text] [Related]
4. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells.
Minko T; Paranjpe PV; Qiu B; Lalloo A; Won R; Stein S; Sinko PJ
Cancer Chemother Pharmacol; 2002 Aug; 50(2):143-50. PubMed ID: 12172980
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of poly(ethylene glycol)-camptothecin conjugate: the inhibition of tumor growth in vivo.
Yu D; Peng P; Dharap SS; Wang Y; Mehlig M; Chandna P; Zhao H; Filpula D; Yang K; Borowski V; Borchard G; Zhang Z; Minko T
J Control Release; 2005 Dec; 110(1):90-102. PubMed ID: 16271793
[TBL] [Abstract][Full Text] [Related]
6. In vivo antitumor activity of camptothecin incorporated in liposomes formulated with an artificial lipid and human serum albumin.
Watanabe M; Kawano K; Toma K; Hattori Y; Maitani Y
J Control Release; 2008 May; 127(3):231-8. PubMed ID: 18384903
[TBL] [Abstract][Full Text] [Related]
7. Novel camptothecin analogue (gimatecan)-containing liposomes prepared by the ethanol injection method.
Stano P; Bufali S; Pisano C; Bucci F; Barbarino M; Santaniello M; Carminati P; Luisi PL
J Liposome Res; 2004; 14(1-2):87-109. PubMed ID: 15461935
[TBL] [Abstract][Full Text] [Related]
8. Preparation and evaluation of lipid vesicles of camptothecin as targeted drug delivery system.
Prabhakara P; Zenia T; Marina K; Shama KP; Girish SN; Matapady NH
Pak J Pharm Sci; 2013 Jul; 26(4):779-86. PubMed ID: 23811458
[TBL] [Abstract][Full Text] [Related]
9. Camptothecin in sterically stabilized phospholipid micelles: a novel nanomedicine.
Koo OM; Rubinstein I; Onyuksel H
Nanomedicine; 2005 Mar; 1(1):77-84. PubMed ID: 17292061
[TBL] [Abstract][Full Text] [Related]
10. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats.
Dadashzadeh S; Vali AM; Rezaie M
Int J Pharm; 2008 Apr; 353(1-2):251-9. PubMed ID: 18191511
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the cytotoxic effect of camptothecin solid lipid nanoparticles on MCF7 cells.
Acevedo-Morantes CY; Acevedo-Morantes MT; Suleiman-Rosado D; RamÃrez-Vick JE
Drug Deliv; 2013 Nov; 20(8):338-48. PubMed ID: 24024505
[TBL] [Abstract][Full Text] [Related]
12. The Effect of Lipid Composition on the Liposomal Delivery of Camptothecin Developed by Active Click Loading.
Xie L; Zhang Q; Zhu Q; Wang Y; Niu S; Zhang X; Huang Y; Li J; Liu X; Xue Z; Zhao X; Zheng Y
Mol Pharm; 2024 May; 21(5):2327-2339. PubMed ID: 38576375
[TBL] [Abstract][Full Text] [Related]
13. Artificial lipids stabilized camptothecin incorporated in liposomes.
Maitani Y; Katayama S; Kawano K; Hayama A; Toma K
Biol Pharm Bull; 2008 May; 31(5):990-3. PubMed ID: 18451532
[TBL] [Abstract][Full Text] [Related]
14. Poly(ethylene glycol) shell-sheddable nanomicelle prodrug of camptothecin with enhanced cellular uptake.
Wu Q; Du F; Luo Y; Lu W; Huang J; Yu J; Liu S
Colloids Surf B Biointerfaces; 2013 May; 105():294-302. PubMed ID: 23384692
[TBL] [Abstract][Full Text] [Related]
15. Liposome formulation of poorly water soluble drugs: optimisation of drug loading and ESEM analysis of stability.
Mohammed AR; Weston N; Coombes AG; Fitzgerald M; Perrie Y
Int J Pharm; 2004 Nov; 285(1-2):23-34. PubMed ID: 15488676
[TBL] [Abstract][Full Text] [Related]
16. Liposome encapsulation of zoledronic acid results in major changes in tissue distribution and increase in toxicity.
Shmeeda H; Amitay Y; Tzemach D; Gorin J; Gabizon A
J Control Release; 2013 May; 167(3):265-75. PubMed ID: 23419948
[TBL] [Abstract][Full Text] [Related]
17. Liposome transport of hydrophobic drugs: gel phase lipid bilayer permeability and partitioning of the lactone form of a hydrophobic camptothecin, DB-67.
Joguparthi V; Xiang TX; Anderson BD
J Pharm Sci; 2008 Jan; 97(1):400-20. PubMed ID: 17879989
[TBL] [Abstract][Full Text] [Related]
18. Effect of surface charge and density of distearylphosphatidylethanolamine-mPEG-2000 (DSPE-mPEG-2000) on the cytotoxicity of liposome-entrapped ricin: effect of lysosomotropic agents.
Rathore SS; Ghosh PC
Int J Pharm; 2008 Feb; 350(1-2):79-94. PubMed ID: 17913409
[TBL] [Abstract][Full Text] [Related]
19. Preparation of camptothecin-loaded polymeric micelles and evaluation of their incorporation and circulation stability.
Watanabe M; Kawano K; Yokoyama M; Opanasopit P; Okano T; Maitani Y
Int J Pharm; 2006 Feb; 308(1-2):183-9. PubMed ID: 16324807
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and optimization of a bifunctional hyaluronan-based camptothecin prodrug.
Xu Z; Zheng W; Yin Z
Arch Pharm (Weinheim); 2014 Apr; 347(4):240-6. PubMed ID: 24402828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
